Medivolve Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

David Preiner

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.3yrs
Eigentum des Geschäftsführers	1.6%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Preiner im Vergleich zu den Einnahmen von Medivolve verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$4m
Sep 30 2023	n/a	n/a	-CA$9m
Jun 30 2023	n/a	n/a	-CA$10m
Mar 31 2023	n/a	n/a	-CA$15m
Dec 31 2022	CA$4m	CA$260k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$7m
Jun 30 2022	n/a	n/a	CA$2m
Mar 31 2022	n/a	n/a	CA$2m
Dec 31 2021	CA$1m	CA$146k	-CA$7m

Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von David im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt US angemessen ist.

Entschädigung vs. Einkommen: DavidDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

David Preiner

3.3yrs

Amtszeit

CA$4,059,393

Vergütung

Mr. David Preiner is Founder, President, CEO and Director of Exponential Genomics Inc. He studied at Harvard University (Ext. BLA candidate) - Biology, Engineering Sciences, Nanotechnology and has experien...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael McCarthy	Member of Advisory Board	4.3yrs	keine Daten	keine Daten
James Beeland Rogers	Member of Strategic Advisory Board	4.3yrs	keine Daten	keine Daten
Joseph Sugerman	Member of Advisory Board	4.2yrs	keine Daten	keine Daten
Glenn Copeland	Member of Advisory Board	no data	keine Daten	keine Daten
Richard Dolan	Member of Strategic Advisory Board	4.3yrs	keine Daten	keine Daten
Paulo Iglessias	Member of Advisory Board	4.3yrs	keine Daten	keine Daten
Mike Mancias	Member of Advisory Board	4.3yrs	keine Daten	keine Daten

4.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: MEDV.FDie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).

Medivolve Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Medivolve Inc. Announces Resignation of Peter Michel as Chief Financial Officer

Medivolve Inc. Announces the Resignation of Wen Ye as Board of Director

Medivolve Inc. Announces the Resignation of Beverley Richardson from its Board of Directors

Medivolve Inc. Announces Chief Financial Officer Changes

Beverly Richardson Joins Questcap’s Board of Directors

Recent updates

Medivolve Inc. Announces Resignation of Peter Michel as Chief Financial Officer

Medivolve Inc. Announces the Resignation of Wen Ye as Board of Director

Medivolve Inc. Announces the Resignation of Beverley Richardson from its Board of Directors

Medivolve Inc. announced that it expects to receive CAD 4 million in funding

Medivolve Inc. announced that it has received CAD 1.2 million in funding

Medivolve Inc. Announces Chief Financial Officer Changes

Medivolve Inc. announced that it expects to receive CAD 2.6 million in funding

Medivolve Announces New COVID-19 Testing Mobile Vans Expanding On-Site Testing Opportunities to Schools, Workplaces, and Events

Medivolve Inc. announced that it has received CAD 12 million in funding

Medivolve Inc. (OTCPK:COPR.F) completed the acquisition of Electronic Health Platform of Myosin Inc.

Medivolve Inc. (OTCPK:COPR.F) signed a binding agreement to acquire Marbella Pharmacy for $0.5 million.

Medivolve Inc. and Marvel Diagnostics Inc. Complete First Stage Clinical Testing of BlowFISH

Medivolve Inc. Launches Business to Business Sales Initiatives

Medivolve Inc. (OTCPK:COPR.F) has signed a letter of intent to acquire Modern Rx LLC for $0.35 million.

Medivolve Inc. Announces the Launch of an Operating Model with Besser Brands in the State of Florida

Medivolve Inc. (NEOE:MEDV) signed a binding letter of intent to acquire Karland Health, LLC.

Medivolve Inc Collection Sites Provides Update with January Sales of 73,973 Tests At an Average Price of $96 Per Test

Medivolve Inc. (NEOE:MEDV) entered into an agreement to acquire Noble Bioscience Corp.

Medivolve Inc. (NEOE:MEDV) entered into a share purchase agreement to acquire a 13.2% stake in Marvel Diagnostics Inc. for $0.33 million.

Medivolve Inc. announced that it has received CAD 5 million in funding

Beverly Richardson Joins Questcap’s Board of Directors

QuestCap Provides COVID-19 Testing Kits to Kinross Gold’s Russian Operations

QuestCap Inc. announced that it expects to receive CAD 5 million in funding

QuestCap Inc. Sign Fifteen Lease Agreements Between Collection Sites, Llc and Orange County, and H&S Energy, Llc to Begin the Roll Out Network of Pop-Up Covid-19 Testing Sites

QuestCap Inc. (CNSX:QSC) completed the acquisition of Collection Sites, LLC.

QuestCap Inc. (CNSX:QSC) entered into a binding letter of intent to acquire Collection Sites, LLC for CAD 2.8 million.

QuestCap Inc. (CNSX:QSC) entered into arm's length agreement to acquire 40% stake in Spectral Analytics, Inc. for $2 million.

QuestCap Inc. (CNSX:QSC) acquired 40% issued and outstanding shares in Amino Therapeutics, Inc.

QuestCap Inc. (CNSX:QSC) completed the acquisition of 49% stake in Athletics and Health Solutions Inc.

QuestCap Inc. (CNSX:QSC) entered into a binding letter of agreement to acquire 28% stake in Sanaty IPS S.A.S. from Latin-Canada Pharma Inc. for CAD 2.7 million.